Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 53 Lung Neoplasms 24 Breast Neoplasms 22 Head and Neck Neoplasms 14 Adenocarcinoma of Lung 11 Neoplasms 7 Esophageal Neoplasms 7 Brain Neoplasms 7 Prostatic Neoplasms 6 Adenocarcinoma, Bronchiolo-Alveolar 6 Neoplasm Metastasis 5 Glioblastoma 5 Adenocarcinoma Of Esophagus 5 Squamous Cell Carcinoma of Head and Neck 4 Rectal Neoplasms 4 Ovarian Neoplasms 4 Gliosarcoma 4 Colorectal Neoplasms 4 Colonic Neoplasms 4 Adenocarcinoma 4 Urinary Bladder Neoplasms 3 Kidney Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Carcinoma, Renal Cell 3 Stomach Neoplasms 2 Skin Neoplasms 2 Neoplasms, Squamous Cell 2 Mesothelioma, Malignant 2 Lymphoid Interstitial Pneumonia 2 Laryngeal Diseases 2

Interventions

Cisplatin 8 Etoposide 6 Paclitaxel 5 Ifosfamide 4 Sunitinib 3 Oxaliplatin 3 Cyclophosphamide 3 Brentuximab Vedotin 3 tremelimumab 2 pembrolizumab 2 etoposide phosphate 2 durvalumab 2 Sirolimus 2 Gemcitabine 2 Everolimus 2 Epirubicin 2 Dexamethasone 2 Carboplatin 2 Bleomycin 2 Bevacizumab 2 tozuleristide 1 rolapitant 1 ribociclib 1 pegfilgrastim 1 pazopanib 1 olaparib 1 fosaprepitant 1 fludarabine phosphate 1 fludarabine 1 cabozantinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Germ Cell and Embryonal × Gefitinib × Clear all

NCT00198159 2014-09-19

IUCRO-0021

Indiana University

Phase 2 Terminated

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡